Experimental HIV Drugs
Experimental HIV Drugs
Ribonucleoside Analogs May Be Potential New Class of HIV Drug
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 10 January 2014 00:00
- Written by University of Lund
A set of compounds known as ribonucleoside analogs -- related to the nucleoside/nucleotide reverse transcriptase inhibitors that currently form the backbone of combination antiretroviral therapy -- demonstrated activity against HIV in laboratory studies, halting viral replication by interrupting HIV DNA production or causing lethal mutations, according to a report in the January 2014 Journal of Virology.
ViiV Requests FDA Approval for Dolutegravir Single-tablet Regimen for HIV
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 25 October 2013 00:00
- Written by ViiV Healthcare
ViiV Healthcare announced this week that it has submitted a New Drug Application for U.S. Food and Drug Administration (FDA) approval of a new all-in-1 pill containing the HIV integrase inhibitor dolutegravir (brand name Tivicay) plus abacavir and lamivudine (the drugs in Epzicom).
Simeprevir for Hepatitis C Approved in Japan, Cobicistat Gets Nod in Europe
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 September 2013 00:00
- Written by Medivir, Gilead Sciences
The HCV protease inhibitor simeprevir (formerly TMC435) has been granted approval in Japan for the treatment of people with genotype 1 chronic hepatitis C, Medivir announced this week. In related news, Gilead Sciences said their new pharmacoenhancer cobicistat -- brand name Tybost -- has been approved as a stand-alone drug in the European Union for use as a booster for certain HIV protease inhibitors.
EACS 2013: Cenicriviroc Shows Good Activity Against HIV, New Formulation May Reduce Dropouts
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 17 October 2013 00:00
- Written by Liz Highleyman
The dual CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and tolerability in a Phase 2 clinical trial, according to a report at the 14th European AIDS Conference (EACS 2013) this week in Brussels. The study had many dropouts, likely due to its complex dosing regimen, but a more user-friendly cenicriviroc formulation has since been developed.
ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 17 September 2013 00:00
- Written by Liz Highleyman
A pair of next-generation HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) demonstrated promising activity in early studies, researchers reported last week at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver. AIC292 showed good antiviral activity in early laboratory, animal and human studies. MK-1439, now in Phase 2b, is likely to interact with ritonavir, but not tenofovir.
Web Design and Development by